BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...
BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited.
METHODS: Adu...
Objective: Esketamine nasal spray (ESK) plus a newly initiated antidepressant (AD) reduces depression symptoms in patients with treatment-resistant depression (TRD), in a subset meeting s...
Objective: The current analysis utilized PatientsLikeMe (PLM) data to compare patient-reported experiences in patients with major depressive disorder (MDD) with suicidal ideation (MDSI) t...